Skip to main content
Top
Published in: Critical Care 1/2019

Open Access 01-12-2019 | Septicemia | Letter

Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes

Authors: Daisuke Hasegawa, Osamu Nishida

Published in: Critical Care | Issue 1/2019

Login to get access

Excerpt

Letter to the editor …
Literature
1.
go back to reference Shimomura Y, Suga M, Kuriyama N, Nakamura T, Sakai T, Kato Y, et al. Recombinant human thrombomodulin inhibits neutrophil extracellular trap formation in vitro. J Intensive Care. 2016;4:48.CrossRef Shimomura Y, Suga M, Kuriyama N, Nakamura T, Sakai T, Kato Y, et al. Recombinant human thrombomodulin inhibits neutrophil extracellular trap formation in vitro. J Intensive Care. 2016;4:48.CrossRef
2.
4.
go back to reference Zhang Z, Zhang G, Goyal H, Mo L, Hong Y. Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation: a latent profile analysis. Crit Care. 2018;22:347.CrossRef Zhang Z, Zhang G, Goyal H, Mo L, Hong Y. Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation: a latent profile analysis. Crit Care. 2018;22:347.CrossRef
Metadata
Title
Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes
Authors
Daisuke Hasegawa
Osamu Nishida
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2019
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-019-2521-7

Other articles of this Issue 1/2019

Critical Care 1/2019 Go to the issue